Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation statusMichael C. Heinrich, G. D. Demetri, Charles M. Baum et al.|Journal of Clinical Oncology|2006Cited by 83